Manitimus is an inhibitor of dihydroorotate dehydrogenase and a potent immunosuppressive agent; it significantly reduces neointimal area and percentage of stenosis in rat models, and attenuates the increase in intimal and medial cross-sectional area and medial wall thickness of vein grafts induced by CMV infection.